Cipla Assessed $15.5 Million In Interest On Indian Drug Overcharge Fine
This article was originally published in PharmAsia News
Executive Summary
India's drug-price regulator dunned Cipla an additional $15.5 million in interest stemming from an earlier charge of overpricing its drugs. The company said the National Pharmaceutical Pricing Authority assessed the interest for April 2007, through January, 2008, on a previous assessment of $186.3 million for overcharges. Among the drugs cited were the firm's ciprofloxacin, norfloxacin, salbutamol and theophyline drugs. (Click here for more